Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin 9-NC) [rubitecan] Versus Most Appropriate Therapy in Refractory Pancreatic Cancer Patients.
Latest Information Update: 29 Jan 2020
At a glance
- Drugs Rubitecan (Primary) ; Fluorouracil; Gemcitabine; Mitomycin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astex Pharmaceuticals
- 23 Jul 2008 Astex Pharmaceuticals added as trial associate as reported by ClinicalTrials.gov.
- 23 Jul 2008 Trial Centre updated as reported by ClinicalTrials.gov.
- 04 Oct 2005 New trial record.